Literature DB >> 9810319

Combined treatment of inoperable carcinomas of the uterine cervix with radiotherapy and regional hyperthermia. Results of a phase II trial.

S Dinges1, C Harder, R Wurm, A Buchali, J Blohmer, J Gellermann, P Wust, H Randow, V Budach.   

Abstract

AIM: The disappointing results for inoperable, advanced tumors of the uterine cervix after conventional radiotherapy alone necessitates improving of radiation therapy. Simultaneous chemotherapy or altered radiation fractionation, such as accelerated regimen, increase acute toxicity and treatment is often difficult to deliver in the planned manner. The purpose of this phase II study was to investigate the toxicity and effectiveness of a combined approach with radiotherapy and regional hyperthermia. PATIENTS AND METHODS: From January 1994 to October 1995 18 patients with advanced carcinomas of the uterine cervix were treated in combination with radiotherapy and hyperthermia. The patients were treated with 6 to 20 MV photons delivered by a linear accelerator in a 4-field-box technique to a total dose of 50.4 Gy in 28 fractions. In the first and fourth week 2 regional hyperthermia treatments were each applied with the Sigma-60 applicator from a BSD-2000 unit. After this a boost to the primary tumor was given with high-dose-rate iridium-192 brachytherapy by an afterloading technique with 4 x 5 Gy at point A to a total of 20 Gy and for the involved parametrium anterioposterior-posterioanterior to 9 Gy in 5 fractions.
RESULTS: The acute toxicity was low and similar to an external radiotherapy alone treatment. No Grade III/IV acute toxicity was found. The median age was 47 years (range 34 to 67 years). In 16 of 18 patients a rapid tumor regression was observed during combined thermo-radiotherapy, which allowed the use of intracavitary high-dose-rate brachytherapy in these cases. Complete and partial remission were observed in 13 and 4 cases, respectively. One patient did not respond to the treatment. The median follow-up was 24 months (range 17 to 36 months). The local tumor control rate was 48% at 2 years. Median T20, T50 and T90 values were 41.7 degrees C (range 40.3 to 43.2 degrees C), 41.1 degrees C (range 39.2 to 42.5 degrees C) and 39.9 degrees C (range 37.7 to 41.9 degrees C), respectively. Cumulative minutes of T90 > 40 degrees C (Cum40T90) and cumulative minutes, which were isoeffective to 43 degrees C, were calculated (CEM43T90, CEM43T50, CEM43T20). CEM43T90 was found to be a significant parameter in terms of local tumor control for the 4 hyperthermia treatments (p = 0.019).
CONCLUSIONS: This treatment modality has proved to be feasible and well tolerable. The rapid tumor shrinkage in the combined approach of radiotherapy with hyperthermia before beginning brachytherapy seems to be a good prerequisite for improving of the disappointing results in cure of advanced cancer of the uterine cervix.

Entities:  

Mesh:

Year:  1998        PMID: 9810319     DOI: 10.1007/bf03038984

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  13 in total

1.  Hyperthermia in clinical oncology. 5th European BSD-users conference, May 18-19, 1990. Rotterdam, The Netherlands.

Authors:  J van der Zee; G C van Rhoon
Journal:  Strahlenther Onkol       Date:  1991-01       Impact factor: 3.621

2.  Effect of tumor size on the prognosis of carcinoma of the uterine cervix treated with irradiation alone.

Authors:  C A Perez; P W Grigsby; S M Nene; H M Camel; A Galakatos; M S Kao; M A Lockett
Journal:  Cancer       Date:  1992-06-01       Impact factor: 6.860

3.  Side-effects of local hyperthermia: results of a prospectively randomized clinical study.

Authors:  S Sharma; A P Sandhu; F D Patel; S Ghoshal; B D Gupta; N S Yadav
Journal:  Int J Hyperthermia       Date:  1990 Mar-Apr       Impact factor: 3.914

4.  Quality control of the SIGMA applicator using a lamp phantom: a four-centre comparison.

Authors:  P Wust; H Fähling; R Felix; S Rahman; R D Issels; H Feldmann; G van Rhoon; J van der Zee
Journal:  Int J Hyperthermia       Date:  1995 Nov-Dec       Impact factor: 3.914

5.  Patterns of care outcome studies. Results of the national practice in cancer of the cervix.

Authors:  G E Hanks; D F Herring; S Kramer
Journal:  Cancer       Date:  1983-03-01       Impact factor: 6.860

Review 6.  Radiation therapy of cervical cancer. New developments.

Authors:  V A Marcial; L V Marcial
Journal:  Cancer       Date:  1993-02-15       Impact factor: 6.860

7.  Cumulative minutes with T90 greater than Tempindex is predictive of response of superficial malignancies to hyperthermia and radiation.

Authors:  K A Leopold; M W Dewhirst; T V Samulski; R K Dodge; S L George; J L Blivin; L R Prosnitz; J R Oleson
Journal:  Int J Radiat Oncol Biol Phys       Date:  1993-04-02       Impact factor: 7.038

8.  Radiation therapy in the management of cancer of the cervix.

Authors:  C A Pérez
Journal:  Oncology (Williston Park)       Date:  1993-02       Impact factor: 2.990

9.  Sensitivity of hyperthermia trial outcomes to temperature and time: implications for thermal goals of treatment.

Authors:  J R Oleson; T V Samulski; K A Leopold; S T Clegg; M W Dewhirst; R K Dodge; S L George
Journal:  Int J Radiat Oncol Biol Phys       Date:  1993-01-15       Impact factor: 7.038

10.  Carcinoma of the cervix: patterns of care studies: review of 1978, 1983, and 1988-1989 surveys.

Authors:  G S Montana; A L Hanlon; T J Brickner; J B Owen; G E Hanks; C C Ling; R Komaki; V A Marcial; G M Thomas; R Lanciano
Journal:  Int J Radiat Oncol Biol Phys       Date:  1995-07-30       Impact factor: 7.038

View more
  8 in total

Review 1.  Ultrasound Hyperthermia Technology for Radiosensitization.

Authors:  Lifei Zhu; Michael B Altman; Andrei Laszlo; William Straube; Imran Zoberi; Dennis E Hallahan; Hong Chen
Journal:  Ultrasound Med Biol       Date:  2019-02-14       Impact factor: 2.998

2.  Endocervical ultrasound applicator for integrated hyperthermia and HDR brachytherapy in the treatment of locally advanced cervical carcinoma.

Authors:  Jeffery H Wootton; I-Chow Joe Hsu; Chris J Diederich
Journal:  Med Phys       Date:  2011-02       Impact factor: 4.071

Review 3.  Modelling of endoluminal and interstitial ultrasound hyperthermia and thermal ablation: applications for device design, feedback control and treatment planning.

Authors:  Punit Prakash; Vasant A Salgaonkar; Chris J Diederich
Journal:  Int J Hyperthermia       Date:  2013-06       Impact factor: 3.914

Review 4.  Combined use of hyperthermia and radiation therapy for treating locally advanced cervix carcinoma.

Authors:  Ludy Lutgens; Jacoba van der Zee; Madelon Pijls-Johannesma; Danielle Fm De Haas-Kock; Jeroen Buijsen; Ghislaine Apg van Mastrigt; Guido Lammering; Dirk K M De Ruysscher; Philippe Lambin
Journal:  Cochrane Database Syst Rev       Date:  2010-03-17

5.  The effect of thermal dose on hyperthermia-mediated inhibition of DNA repair through homologous recombination.

Authors:  Nathalie van den Tempel; Charlie Laffeber; Hanny Odijk; Wiggert A van Cappellen; Gerard C van Rhoon; Martine Franckena; Roland Kanaar
Journal:  Oncotarget       Date:  2017-07-04

6.  Impact of Number of Segmented Tissues on SAR Prediction Accuracy in Deep Pelvic Hyperthermia Treatment Planning.

Authors:  Iva VilasBoas-Ribeiro; Gerard C van Rhoon; Tomas Drizdal; Martine Franckena; Margarethus M Paulides
Journal:  Cancers (Basel)       Date:  2020-09-16       Impact factor: 6.639

Review 7.  Clinical Evidence for Thermometric Parameters to Guide Hyperthermia Treatment.

Authors:  Adela Ademaj; Danai P Veltsista; Pirus Ghadjar; Dietmar Marder; Eva Oberacker; Oliver J Ott; Peter Wust; Emsad Puric; Roger A Hälg; Susanne Rogers; Stephan Bodis; Rainer Fietkau; Hans Crezee; Oliver Riesterer
Journal:  Cancers (Basel)       Date:  2022-01-26       Impact factor: 6.639

8.  Biological modelling of the radiation dose escalation effect of regional hyperthermia in cervical cancer.

Authors:  J Crezee; C M van Leeuwen; A L Oei; L E van Heerden; A Bel; L J A Stalpers; P Ghadjar; N A P Franken; H P Kok
Journal:  Radiat Oncol       Date:  2016-02-02       Impact factor: 3.481

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.